Edgewise Therapeutics, Inc.
Edgewise Therapeutics is a biopharmaceutical company developing small-molecule medicines for people with serious muscle diseases. Its proprietary drug discovery platform targets key proteins in skeletal and cardiac muscle, with programs initially focused on rare neuromuscular and cardiac diseases. The muscular dystrophy program includes sevasemten, an oral candidate being studied in Duchenne and Becker muscular dystrophies. Its cardiovascular program includes EDG-7500, being studied in obstructive and nonobstructive hypertrophic cardiomyopathy, and EDG-15400, in a Phase 1 trial. The preclinical EDG-003 program explores candidates for cardiometabolic diseases. Edgewise retains global development and commercialization rights to its programs. It is developing candidates for potential future sale as medicines, including plans to market approved products in the United States and to evaluate collaborations outside the country. Edgewise is headquartered in Boulder, Colorado.
No SEC Form 4 filings for $EWTX in the last 30 days.
See all $EWTX insider activity →Edgewise Therapeutics (EWTX) submitted a Phase 3 protocol for EDG-7500, a drug for hypertrophic cardiomyopathy, to the FDA. The STRATUS-HCM trial will include 600 adults, with primary endpoint being change in peak oxygen consumption after 24 weeks. The company plans to start the trial in Q4 2026, with consistent feedback from global regulators.
Edgewise Therapeutics (EWTX) reported Q3 2026 results, highlighting progress in cardiovascular programs. EDG-7500 Phase 3 trial for HCM expected by year-end 2026. EDG-15400 Phase 2 trial for HFpEF initiated. Q3 revenue included $1.348B gain from sevasemten sale. Cash reserves at $1.744B.
William Blair initiated coverage on Edgewise Therapeutics (EWTX) with an outperform rating and a $53 price target. The stock is up 149% over the past year, trading at $38.20. The company has $2B in cash and focuses on cardiovascular disease treatments, with key catalysts expected in 2026-2027. H.C. Wainwright reiterated its Buy rating with a $57 target.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning EWTX (Edgewise Therapeutics, Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent EWTX coverage spans insider activity, financial news and technology.
The protocol filing introduces a new, sizable clinical program that could drive future upside if data are positive.
Positive cash infusion and clinical progress suggest upside potential.
Analyst initiation and upgraded valuation could lift the stock.
First‑in‑human dosing may boost investor sentiment as the trial progresses.
Positive Phase 2 safety data and a clear path to Phase 3 could lift sentiment and attract biotech investors.
AlphAI scores every news story that mentions EWTX with an AI model for sentiment and relevance, and aggregates insider trades from Edgewise Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Edgewise Therapeutics (EWTX) submitted a Phase 3 protocol for EDG-7500, a drug for hypertrophic cardiomyopathy, to the FDA. The STRATUS-HCM trial will include 600 adults, with primary endpoint being change in peak oxygen consumption after 24 weeks. The company plans to start the trial in Q4 2026, with consistent feedback from global regulators.
Edgewise Therapeutics (EWTX) reported Q3 2026 results, highlighting progress in cardiovascular programs. EDG-7500 Phase 3 trial for HCM expected by year-end 2026. EDG-15400 Phase 2 trial for HFpEF initiated. Q3 revenue included $1.348B gain from sevasemten sale. Cash reserves at $1.744B.
William Blair initiated coverage on Edgewise Therapeutics (EWTX) with an outperform rating and a $53 price target. The stock is up 149% over the past year, trading at $38.20. The company has $2B in cash and focuses on cardiovascular disease treatments, with key catalysts expected in 2026-2027. H.C. Wainwright reiterated its Buy rating with a $57 target.
Edgewise Therapeutics (EWTX) dosed the first patient in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a treatment for heart failure with preserved ejection fraction (HFpEF). The trial will enroll 90 adults and evaluate safety, tolerability, and efficacy of EDG-15400. Data will be presented at HFSA 2026. HFpEF affects cardiac relaxation, and EDG-15400 aims to address this.
Edgewise Therapeutics (EWTX) announced preclinical data showing its cardiac sarcomere modulator EDG-7500 improves cardiac relaxation while preserving systolic function. The company will host a webcast to discuss these findings. EDG-7500 is being evaluated for hypertrophic cardiomyopathy (HCM) and a Phase 3 trial is expected to begin in Q4 2026. Early clinical observations align with preclinical data, and a peer-reviewed publication is set to release.
Edgewise Therapeutics (EWTX) saw significant options activity, with a 6,000-contract diagonal spread indicating a bullish stance. Traders rolled ITM Sep $45 calls to OTM Oct $50 calls, targeting an 8.4% rally. EWTX stock is up 197% over the past year, driven by a $2.65B business sale. Analysts have mixed views on its valuation and profitability.
Russell Alan J (Chief Scientific Officer) sold 5,901 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.73 ($43.68–$44.46, $0.26M total) across 3 trades on 2026-08-12.
MOORE JOHN R (General Counsel) sold 5,016 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.82 ($43.80–$44.50, $0.22M total) across 4 trades on 2026-08-12.
Derakhshan Behrad (Chief Business Officer) sold 5,100 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.81 ($43.70–$44.50, $0.22M total) across 4 trades on 2026-08-12.
KOCH KEVIN (President and CEO) sold 17,971 shares of Edgewise Therapeutics, Inc. (EWTX) at an average of $43.68 ($43.64–$44.33, $0.79M total) across 3 trades on 2026-08-12.
